KBI Biopharma 新闻与活动
在场
KBI Biopharma 的所有者是 JSR.
JSR 是一家在股票代码 4185 (JP) 下上市的公司。
JSR 在 3 个国家有直接业务。JSR 拥有 5家子公司，其中包括 Crown Bioscience、Indivumed Services 和 Inpria。
他们在：
高管
查看带有其 14 名主要高管的组织结构图
KBI Biopharma 搜索最多的简介
- Tim Lowery, Chief Executive Officer
- Peter Carbone, Chief Operating Officer
- Marykay Marchigiani, Chief Financial Officer
高管在JSR变化
- Eric Johnson 曾任 Representative Director and Chief Executive Officer, 将于 20254月1 现任 Director (新闻发布的2025三月26号).
- Tetsuro Hori 曾任 Vice President, Chief Financial Officer, Chief Legal Officer and Director, 将于 20254月1 升职为 President, Chief Executive Officer and Representative Director (新闻发布的2025三月26号).
创建提醒
跟踪 KBI Biopharma 的高管变动
生物技术
JSR 拥有 2,346 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Genus (联合王国)。
Popular M&A news in 生物技术
- Ernexa Therapeutics的新名称是Ernexa Therapeutics。 (公布2025三月26号).
- Tempero Bio 刚刚宣布为 70 筹款数百万美元。 (公布2025三月25号).
- 23andMe has filed for bankruptcy protection 23andMe (公布2025三月25号).
生物技术 行业的其他推荐联系人
消息
KBI Biopharma 的最新新闻稿
- KBI Biopharma to Lead Development and Manufacturing of Alanis Therapeutics’ Antagonistic Antibody Candidate
- Following a Successful FDA Inspection, KBI Biopharma Extends and Expands Commercial Contract with Leading Global Pharmaceutical Company
- KBI Biopharma Appoints Jean-Baptiste Agnus as Chief Business Officer
- KBI Biopharma Strengthens Quality and Regulatory Affairs Expertise with Appointment of Chief Quality Officer
- KBI Biopharma Recognized as a Leader in All Six Categories of the 2024 CDMO Leadership Awards
- KBI Biopharma, Inc. and Argonaut Manufacturing Services, Inc. Forge Strategic Alliance to Support Global Biopharmaceutical Companies with Integrated Drug Substance and Drug Product Solutions
- KBI Biopharma, Inc. Appoints Maggie Chen as Site Head of Patriot Park Mammalian cGMP Manufacturing Facility
- KBI Biopharma, Inc. Expands Global Portfolio with Launch of SUREmAb™ for Faster Monoclonal Antibody Development and Manufacturing
- KBI Biopharma Continues to Strengthen Leadership and Expertise With Key Executive Appointments
- KBI's Leadership Team Discusses Operational Consolidation with Selexis at BIO International 2023
- View more press releases Close
